Background
==========

Studies have shown that lower estimated glomerular filtration (eGFR) and higher albumin to creatine ratio (ACR) are strong, independent risk factors for incident heart failure \[[@B1]-[@B3]\]. However, how chronic kidney disease (CKD) leads to heart failure is not fully understood; specifically, we lack information on which biological mediators of CKD initiate myocardial injury and whether certain subgroups of patients with CKD are more susceptible to myocardial injury. High sensitivity cardiac troponin T (hs-TnT) independently predicts cardiovascular mortality in populations with or without cardiac disease \[[@B4]-[@B6]\], and predicts cardiovascular events \[[@B7],[@B8]\] and all-cause mortality \[[@B9]\] in patients with CKD and end-stage renal disease \[[@B10]\]. Since the highly sensitive assay detects much lower levels of myocardial injury than prior assays, it may be useful for studying the earliest stages of heart disease in subjects with CKD. Our group has shown that hs-TnT is independently associated with left ventricular hypertrophy (LVH) in participants of the CRIC cohort who do not have self-reported cardiovascular disease (CVD) \[[@B11]\]. Additional culprits in the CKD milieu thought to contribute to the development of CVD include inflammation, anemia, and deranged mineral metabolism. Whether these factors are associated with subclinical myocardial injury (as measured by hs-TnT) in a CKD cohort without overt CVD has not been previously studied.

We sought to examine renal and non-renal predictors of subclinical myocardial injury using hs-TnT in subjects without self-reported CVD in the Chronic Renal Insufficiency Cohort (CRIC). First, we hypothesized that lower estimated glomerular filtration rate (eGFR) and higher urine albumin-creatinine ratio (ACR) would be independently associated with higher hs-TnT concentration. Second, we hypothesized that elevated fibroblast growth factor 23 (FGF-23) concentrations, hyperphosphatemia, and anemia would be associated with higher hs-TnT independently of eGFR.

Methods
=======

The Chronic Renal Insufficiency Cohort (CRIC) Study was designed to investigate risk factors for progression of CKD, cardiovascular disease and overall mortality in persons with CKD. Participants were recruited between June 2003 and March 2007 at seven centers (Ann Arbor, Michigan; Baltimore, Maryland; Chicago, Illinois; Cleveland, Ohio; New Orleans, Louisiana; Philadelphia, Pennsylvania; and Oakland, California). Investigators recruited 3939 racially and ethnically diverse individuals between the ages of 21 to 74 years with eGFR between 20 and 70 ml/min/1.73 m^2^ by simplified MDRD equation \[[@B12]\]. Exclusion criteria were as follows: polycystic kidney disease, use of immunosuppression within the last 6 months, institutionalization, inability to consent, enrollment in other studies, pregnancy, New York Heart Association class III to IV heart failure, HIV, cirrhosis, myeloma, renal cancer, recent chemotherapy, organ transplant, or dialysis treatment within the last month \[[@B13]\]. The Institutional Review Board at each study site approved the protocol and participants gave written, informed consent. For this analysis, participants with known self-reported cardiovascular disease, peripheral vascular disease, or heart failure were excluded.

Kidney function was measured using cystatin-based eGFR (eGFRcys) and creatinine-based eGFR using the MDRD equation (eGFRcr). Compared to creatinine, cystatin has been shown to be a better marker of kidney function at higher eGFR \[[@B14]\], and cystatin has a stronger association with cardiovascular outcomes than creatinine-based eGFR (eGFRcr) \[[@B15],[@B16]\]. In CRIC, eGFRcys has a wider distribution of values than eGFRcr because enrollment was based upon a fixed range of eGFR \[[@B17]\]. Samples for cystatin were processed using a Siemens BNII nephelometer at the CRIC central laboratory, with a coefficient of variation (CV) of 4.9%. Values were corrected for drift over time by standardization to calibrator lot 51 and reagent lot 40. Cystatin-c based eGFR was calculated by the CKD-EPI equation \[[@B18]\], and eGFR was categorized as \< 30, 30--44, 45--59, and ≥ 60 ml/min/1.73 m^2^. Urine samples were collected for spot albumin-creatinine ratios (ACR), and ACR was categorized as \< 30, 30--299, 300--999, and ≥ 1000 mg/g.

Information on demographics and clinical history was obtained by self-report on questionnaires administered at the baseline visit. Diabetes was defined as documented medical history, current or previous use of diabetic medications, or elevated fasting blood glucose. Blood pressure was averaged over three measurements performed in a standardized fashion in a seated position at rest using a calibrated sphygmomanometer. Echocardiograms were performed at one year after enrollment and were read at the core echocardiography laboratory (University of Pennsylvania) using guidelines of the American Society of Echocardiography \[[@B19]\]. Left ventricular mass index was derived by the area-length method, indexed to height^2.7^\[[@B19]\]. Hs-TnT was measured at Rapid Response Laboratories, University of Maryland Medical Center with the Roche Elecsys immunoassay (Roche Diagnostics, Indianapolis, Indiana), which has an analytical range of 3 to 10,000 ng/L, and a coefficient of variation of 9% at 13.5 ng/L (the 99th percentile in a healthy reference group) \[[@B20]\].

Statistical analysis
--------------------

Of 2505 subjects without CVD, 2464 had hs-TnT measurements, and of these 474 (19%) were undetectable (\< 3 pg/ml). We first categorized hs-TnT as undetectable (\< 3 pg/ml), Tertile 1 (3--8.6 pg/ml), Tertile II (8.7-17 pg/ml), and Tertile III (17--739 pg/ml). We compared characteristics of participants in these four categories using ANOVA or Kruskal-Wallis tests for continuous variables and Chi-squared tests for categorical variables.

We next performed multivariable regression analysis in order to identify factors with independent associations with hs-TnT. Because such a large proportion of hs-TnT values were undetectable, we used tobit regression, which is designed to handle left-censored values. Undetectable values were assigned the level 1.5 pg/ml. Because hs-TnT is right-skewed, the outcome was log-transformed for analysis. Coefficients were then exponentiated to yield the estimated multiplicative increase attributable to each factor; e.g., an exponentiated coefficient of 1.3 represents a 30% higher hs-TnT in the exposed compared with the unexposed. Initially, the regression model included all candidate covariates with p-value \< 0.05 by univariate analysis. Model 1 was built using backwards stepwise selection until only covariates significant at p \< 0.05 remained. Model 2 was built by adding LV mass and ejection fraction to Model 1. All analyses were performed using STATA 11 (StataCorp LP, College Station, TX).

Results
=======

In this subgroup of CRIC study participants without CVD, hs-TnT was detectable in 81% of subjects, and median (IQR) of hs-TnT was 9.4 pg/ml (4.3-18.3) (Figure [1](#F1){ref-type="fig"}). Increased age, male gender, black race and Hispanic ethnicity were associated with higher TnT, as were diabetes and hypertension. Subjects with higher hs-TnT had lower LDL, lower HDL, higher tryglycerides, lower hemoglobin, higher phosphorus, higher FGF-23, lower eGFRcys and higher ACR (Table [1](#T1){ref-type="table"}).

![**Distribution of high sensitivity troponin t among chronic renal insufficiency cohort participants without self**-**reported cardiovascular disease.** Legend: Hs-TnT was detectable in 81% of subjects; median (IQR) of hs-TnT was 9.4 pg/ml (4.3-18.3). All hs-TnT values greater than 100 pg/ml were truncated in one bar at 100.](1471-2369-14-229-1){#F1}

###### 

Characteristics of chronic renal insufficiency cohort participants with high sensitivity troponin t measurements

                                                **Undetectable**      **Tertile I**        **Tertile II**       **Tertile III**      **P**
  ------------------------------------------- -------------------- -------------------- -------------------- --------------------- ----------
  **Hs**-**TnT (pg/ml)**\*                       1.5 (1.5-1.5)        5.7 (4.6-7.1)       11.9 (10.1-14.2)     30.0 (21.4-45.3)     \< 0.001
  **Age**                                         51.5 (11.8)          55.7 (11.8)          60.3 (10.7)           59.2 (11.1)       \< 0.001
  **Female**                                          75.5                 53.8                 42.7                 29.1           \< 0.001
  **Race**                                                                                                                          \< 0.001
  **Non**-**Hispanic White**                          53.2                 49.9                 45.1                 29.1               
  **Non**-**Hispanic Black**                          33.8                 35.6                 38.0                 45.4               
  **Hispanic**                                        8.4                  9.0                  13.9                 21.4               
  **Other**                                           4.6                  5.6                  3.0                   4.1               
  **Diabetes**                                        14.8                 29.1                 45.1                 68.3           \< 0.001
  **Hypertension**                                    68.6                 82.1                 91.4                 94.7           \< 0.001
  **Current smoking**                                 13.1                 10.4                 11.8                 11.0            0.526
  **SBP (mmHg) †**                                124.1 (16.9)         128.3 (17.3)         132.9 (19.5)         140.5 (20.9)       \< 0.001
  **DBP (mmHg) ‡**                                75.1 (12.1)          75.5 (11.9)          74.3 (12.0)           76.8 (11.8)        0.010
  **BMI (kg/m**^**2**^**) §**                      30.6 (8.5)           31.2 (7.9)           32.3 (8.1)           32.5 (7.5)        \< 0.001
  **HDL (mg/dL) \|\|**                            54.1 (17.7)          50.9 (15.2)          49.1 (16.2)           46.4 (15.4)       \< 0.001
  **LDL (mg/dL)**                                 108.9 (30.4)         107.7 (34.1)         102.4 (34.7)          98.7 (36.3)       \< 0.001
  **Triglycerides (mg/dL)**                      144.2 (114.1)        155.2 (115.1)         149.3 (91.1)         161.3 (108.0)      \< 0.001
  **Total cholesterol (mg/dL)**                   193.7 (37.6)         192.3 (41.4)         184.3 (44.8)         182.0 (45.6)       \< 0.001
  **Serum albumin (g/dL)**                         4.2 (0.4)            4.1 (0.4)            4.1 (0.4)             3.9 (0.5)        \< 0.001
  **hsCRP (mg/L) \#**                              4.9 (8.3)            4.9 (8.8)            5.4 (8.7)             5.7 (9.8)         0.015
  **Hemoglobin (g/dL)**                            13.2 (1.5)           13.2 (1.8)           13.0 (1.8)           12.2 (1.8)        \< 0.001
  **Phosphate (mg/dL)**                            3.6 (0.6)            3.6 (0.5)            3.6 (0.6)             3.9 (0.7)        \< 0.001
  **FGF**-**23 (RU/ml)\*\***                   104.7 (73.8-160.2)   114.6 (81.3-182.5)   137.4 (93.3-208.8)   171.7 (113.9-293.0)   \< 0.001
  **eGFRcys †† (ml/min/1.73 m**^**2**^**)**       66.1 (22.7)          55.9 (19.7)          49.5 (16.3)           40.9 (16.2)       \< 0.001
  **ACR (μg/mg) ψ**                             11.2 (5.0-86.9)      21.3 (5.4-201.7)     30.5 (7.9-279.7)    289.7 (31.4-1393.2)   \< 0.001
  **LV mass (g/m**^**2.7**^**) Ω**                43.8 (10.2)          46.1 (10.4)          50.3 (12.8)           55.4 (13.8)       \< 0.001
  **Ejection fraction (%)**                        55.7 (6.3)           55.9 (6.4)           55.8 (7.4)           54.3 (7.3)        \< 0.001

Mean (SD) or median (IQR) are reported for continuous variables and percentage for categorical variables. P values are obtained using ANOVA or Kruskal-Wallis tests for continuous variables and Chi-squared tests for categorical variables. \* High sensitivity troponin T. † Systolic blood pressure. ‡ Diastolic blood pressure. § Body mass index. \|\| High density lipoprotein. Low density lipoprotein. \# High sensitivity c-reactive protein. \*\* Fibroblast growth factor 23. †† Cystatin-based estimated glomerular filtration rate. ψ Albumin to creatinine ratio. Ω Left ventricular.

After multivariate adjustment, the strongest renal predictor of hs-TnT was eGFRcys. All eGFRcys categories below the referent group of \> 60 ml/min/1.73 m^2^ were associated with incrementally higher hs-TnT. Subjects with eGFRcys \< 30 ml/min/1.73 m^2^ had almost a 3-fold higher hs-TnT than the referent group with eGFRcys \> 60 ml/min/1.73 m^2^. ACR did not show a linear association with hs-TnT; only those subjects with ACR ≥ 1000 mg/g had higher hs-TnT compared to those with ACR \< 30 mg/g. Associations of phosphate and FGF-23 with hs-TnT were significantly attenuated by adjustment, and hemoglobin lost significance with adjustment (compared to referent category of hemoglobin \> 14, hemoglobin \<=11 had 16% higher hs-TnT, p=0.07) (Table [2](#T2){ref-type="table"}). We found an additive effect between eGFRcys and ACR when we further categorized subjects by both of these factors. After multivariate adjustment, those in the lowest eGFR/highest ACR category (eGFRcys\< 30 ml/min/1.73 m^2^ and ACR ≥ 1000) had more than a 4-fold increase in hs-TnT compared to the referent group (eGFRcys\> 60 ml/min/1.73 m^2^ and ACR\< 30) (Figure [2](#F2){ref-type="fig"}).

###### 

Associations between renal factors and high sensitivity troponin t

                                                      **Unadjusted**    **Model 1**     **Model 2**                                   
  ------------------------------------------ ------ ------------------ ------------- ------------------ ---------- ------------------ ----------
  **eGFRcys\* (ml/min/1.73 m**^**2**^**)**                                                                                                 
  ≥ 60                                        757       Reference           \-           Reference                     Reference          \-
  45-59                                       684    2.11 (1.86-2.41)    \< 0.001     1.51 (1.35-1.69)   \< 0.001   1.50 (1.34-1.67)   \< 0.001
  30-44                                       705    3.02 (2.66-3.44)    \< 0.001     1.97 (1.74-2.22)   \< 0.001   1.96 (1.74-2.21)   \< 0.001
  \< 30                                       311    5.27 (4.47-6.21)    \< 0.001     2.90 (2.47-3.41)   \< 0.001   2.83 (2.41-3.33)   \< 0.001
  **ACR (μg/mg) †**                                                                                                                        
  \< 30                                       1115      Reference           \-           Reference                     Reference          \-
  30-299                                      582    1.58 (1.39-1.80)    \< 0.001     1.08 (0.98-1.20)    0.130     1.06 (0.96-1.19)    0.214
  300-999                                     338    1.94 (1.66-2.28)    \< 0.001     1.09 (0.96-1.25)    0.191     1.08 (0.95-1.23)    0.238
  ≥ 1000                                      325    3.61 (3.08-4.23)    \< 0.001     1.56 (1.35-1.81)   \< 0.001   1.53 (1.32-1.77)   \< 0.001
  **Phosphate (mg/dL)**                                                                                                                    
  \< 3                                        265       Reference           \-           Reference                     Reference          \-
  3-3.9                                       1427   1.08 (0.90-1.28)      0.419      1.02 (0.90-1.17)    0.739     1.02 (0.90-1.17)    0.711
  4-4.9                                       646    1.59 (1.31-1.93)    \< 0.001     1.06 (0.91-1.23)    0.445     1.06 (0.92-1.24)    0.412
  ≥ 5                                          81    3.51 (2.52-4.90)    \< 0.001     1.35 (1.04-1.76)    0.023     1.39 (1.08-1.81)    0.012
  **FGF**-**23 ‡**                                                                                                                         
  Quartile I                                  606       Reference                        Reference                     Reference           
  Quartile II                                 606    1.45 (1.25-1.68)    \< 0.001     1.07 (0.96-1.20)    0.230     1.08 (0.96-1.21)    0.206
  Quartile III                                606    2.11 (1.82-2.45)    \< 0.001     1.20 (1.06-1.35)    0.004     1.17 (1.04-1.33)    0.011
  Quartile IV                                 606    2.62 (2.26-3.04)    \< 0.001     1.22 (1.06-1.40)    0.004     1.17 (1.02-1.34)    0.021

\*N's are \# observations among participants with TnT measurements, with 7 observation excluded.

Model 1 adjusted for: age (per SD), female, race, diabetes, SBP categories, albumin (per SD), eGFR_CysC, ACR, and phosphate and FGF-23. Model 2 adjusted for: Model 1 + LV mass, ejection fraction.

eGFRcys=cystatin-based estimated glomerular filtration rate. † albumin to creatinine ratio. ‡ fibroblast growth factor 23.

![**Joint associations of categories of estimated glomerular filtration rate and albumin to creatinine ratio with high sensitivity troponin t in adjusted tobit regression analyses.** Legend: After multivariate adjustment, lower eGFR and higher albuminuria were associated with higher levels of hs-TnT. Final Tobit model adjusted for: age (per SD), female, race, diabetes, SBP categories, albumin (per SD), LV mass, ejection fraction, eGFRcys, ACR, and phosphate and FGF-23 (per SD). SD: standard deviation. SBP: systolic blood pressure. LV: left ventricular. eGFRcys: cystatin- based estimated glomerular filtration rate. ACR: albumin to creatinine ratio. FGF-23: fibroblast growth factor 23.](1471-2369-14-229-2){#F2}

Several non-renal covariates remained strong predictors of hs-TnT after multivariable adjustment. Increased age was associated with higher hs-TnT, and hs-TnT was substantially lower in women compared to men. Compared to non-Hispanic whites, non-Hispanic blacks had significantly higher hs-TnT; although Hispanic participants had higher TnT levels, the association was not significant. Higher LV mass index was associated with higher hs-TnT across all categories of LV mass index; lower ejection fraction was associated with higher hs-TnT mainly in the lowest category (≤ 35%). Diabetes, elevated SBP and lower serum albumin were independently associated with higher hs-TnT (Table [3](#T3){ref-type="table"}). After adjustment, the following markers were not associated with higher hs-TnT (B coefficient per SD (95% CI)): hsCRP 0.98 (0.94-1.02), p=0.386; LDL 1.01 (0.97-1.06), p=0.510; HDL 1.04 (0.99-1.09), p=0.126; triglycerides 0.99 (0.95-1.03), p=0.597. The associations of renal and non-renal covariates were consistent across categories of renal function. Substitution of eGFRcr for eGFRcys did not change our findings.

###### 

**Associations between non**-**renal factors and high sensitivity troponin t**

                                               **Unadjusted**     **Model 1**     **Model 2**                                   
  ---------------------------------- ------- ------------------- ------------- ------------------ ---------- ------------------ ----------
           **Age (per SD)**           2,457   1.39 (1.32-1.46)     \< 0.001     1.31 (1.25-1.37)   \< 0.001   1.31 (1.25-1.37)   \< 0.001
              **Female**              1,190   0.41 (0.37-0.46)     \< 0.001     0.38 (0.35-0.41)   \< 0.001   0.39 (0.36-0.42)   \< 0.001
               **Race**                                                                                                              
            Non-Hisp white            1,075       Reference           \-           Reference          \-         Reference          \-
            Non-Hisp Black             946    1.51 (1.34-1.70)     \< 0.001     1.31 (1.20-1.43)   \< 0.001   1.26 (1.16-1.38)   \< 0.001
               Hispanic                330    2.09 (1.77-2.47)     \< 0.001     1.06 (0.93-1.21)    0.398     1.02 (0.89-1.16)    0.768
                Other                  106    1.10 (0.84-1.44)       0.492      1.03 (0.84-1.25)    0.807     1.02 (0.84-1.24)    0.854
             **Diabetes**             1,009   2.96 (2.68-3.28)     \< 0.001     1.87 (1.71-2.04)   \< 0.001   1.84 (1.69-2.00)   \< 0.001
         **Albumin (per SD)**         2,437   0.72 (0.68-0.76)     \< 0.001     0.92 (0.88-0.96)    0.001     0.93 (0.89-0.98)    0.003
           **SBP (mmHg)\***                                                                                                          
                \< 120                 408        Reference           \-           Reference          \-         Reference          \-
               120-129                 324    1.32 (1.09-1.61)       0.005      1.03 (0.89-1.19)    0.678     1.03 (0.89-1.19)    0.706
               130-139                 321    1.69 (1.39-2.05)     \< 0.001     1.14 (0.98-1.32)    0.081     1.12 (0.97-1.29)    0.139
               140-149                 194    2.03 (1.62-2.55)     \< 0.001     1.24 (1.05-1.47)    0.014     1.22 (1.03-1.44)    0.023
               150-159                 131    2.71 (2.09-3.51)     \< 0.001     1.44 (1.19-1.76)   \< 0.001   1.38 (1.14-1.69)    0.001
                ≥ 160                  163    3.36 (2.64-4.27)     \< 0.001     1.35 (1.12-1.63)    0.001     1.27 (1.06-1.53)    0.011
   **LV mass (g/m**^**2.7**^**) †**                                                                                                  
                \< 40                  474        Reference           \-                                         Reference          \-
                40-59                 1,165   1.94 (1.68-2.24)     \< 0.001                                   1.17 (1.05-1.30)    0.006
                60-79                  284    3.89 (3.20-4.72)     \< 0.001                                   1.39 (1.19-1.63)   \< 0.001
                80-99                  41     3.77 (2.49-5.72)     \< 0.001                                   1.47 (1.04-1.97)    0.018
                ≥ 100                  10     4.85 (2.15-10.95)    \< 0.001                                   1.87 (1.02-3.42)    0.043
      **Ejection fraction (%)**                                                                                                      
                \> 50                 1,845       Reference           \-                                         Reference          \-
                46-50                  197    1.12 (0.92-1.38)       0.253                                    1.13 (0.98-1.31)    0.087
                36-45                  130    1.33 (1.04-1.69)       0.023                                    1.13 (0.95-1.34)    0.184
                 ≤ 35                  22     1.93 (1.09-3.41)       0.024                                    1.64 (1.09-2.48)    0.018

\*N's are \# observations among participants with TnT measurements, with 7 observation excluded.

Model 1 adjusted for: age (per SD), female, race, diabetes, SBP categories, albumin (per SD), eGFR_CysC, ACR, and phosphate and FGF-23. Model 2 adjusted for: Model 1 + LV Mass, ejection fraction. \* Systolic blood pressure. † Left ventricular.

Discussion
==========

In this study of participants without CVD selected from the CRIC cohort, over 80% had detectable levels of hs-TnT. Lower eGFR, higher LV mass, increased age, male gender, black race, diabetes and higher blood pressure were independently associated with higher hs-TnT. Interpreting these associations may help us understand which subjects with CKD are most susceptible to developing coronary disease or heart failure.

The median hs-TnT in our cohort (9 pg/ml) was comparable to subjects with stable coronary artery disease (5--6 pg/ml \[[@B21]\]) and heart failure (13--17 pg/ml \[[@B22]\]). This degree of chronic, low-level troponin release has been attributed to various mechanisms in addition to macrovascular atherosclerotic disease. Left ventricular hypertrophy (LVH) is common in this population, and is associated with higher levels of hs-TnT \[[@B11]\]. Chronic kidney disease may lead to myocardial injury via endothelial dysfunction and microvascular disease caused by elevated levels of asymmetric dimethylarginine (ADMA) \[[@B23]\] or mediators of oxidative stress \[[@B24]\]. Alternatively, the association between lower eGFR and higher TnT could be in part due to reduced renal clearance of troponin T. Troponin T fragments small enough to be cleared by the kidneys have been found in serum of patients with ESRD \[[@B25]\]. However, we also show that LV mass is associated with hs-TnT independently of eGFR; furthermore, 5% of persons with eGFR\< 30 and 10% with eGFR between 30--45 had undetectable hs-TnT, demonstrating that impaired clearance is unlikely to be solely responsible for detectable levels of hs-TnT.

Similar to the Dallas Heart Study in which hs-TnT was studied in a community-based cohort \[[@B4]\] we found that older age, male gender, black race and diabetes were independently associated with elevated hs-TnT. While it seems intuitive that older age and diabetes would be associated with microvascular injury and thus lead to higher hs-TnT, the explanation for male gender and black race is less obvious. Male gender and black race are associated with higher LV mass index \[[@B26]-[@B28]\], but in our study these associations persisted after adjustment for LV mass index. African Americans have been found to have a higher risk of endothelial dysfunction \[[@B29],[@B30]\], and this may explain the higher levels of hs-TnT among them in our cohort.

Prior studies have shown FGF-23 to have strong, independent associations with structural cardiovascular disease including LVH \[[@B31]\], coronary artery disease \[[@B32]\], and carotid intima-media thickness \[[@B33]\]; cardiovascular events \[[@B34]\]; and overall mortality \[[@B13],[@B35]\] in cohorts with prevalent CVD and all stages of CKD \[[@B13]\]. One role of FGF-23 in cardiovascular disease is via induction of left ventricular hypertrophy; FGF-23 injected into mice at concentrations of 800 RU/ml resulted in LVH \[[@B36]\]. In addition, the growth factor was associated with myocardial injury (hs-TnT) in a CKD cohort, an association that was only mildly attenuated by adjustment for LVH \[[@B37]\]. In contrast, we observed only a weak association of FGF-23 with hs-TnT levels with or without adjustment for LV mass index. The fact that we excluded CRIC participants with history of CVD may account for these differences. While FGF-23 does not appear to be a predominant factor for subclinical myocardial injury in CRIC subjects without CVD, it may yet prove crucial in the development of heart failure in this cohort via induction of LVH.

Strengths of our study include the large study cohort, broad range of eGFRcys and ethnic diversity represented by CRIC. The high percentage of participants with detectable hs-TnT increased our power to detect cross-sectional associations. There are also several important limitations. Subjects with known cardiovascular disease were excluded based on history, not left heart catheterization; some subjects with undetected coronary artery disease may have been included. Since our analysis is cross-sectional, we cannot assume a causal relationship between factors associated with hs-TnT and hs-TnT or incident CVD. We cannot separate the relative importance of hs-TnT production vs. clearance as determinants of serum concentrations.

Conclusions
===========

We conclude that in the absence of CVD, the most important renal predictor of higher hs-TnT in the CRIC cohort is lower eGFRcys. Non-renal predictors include age, male gender, black race, diabetes, and higher systolic blood pressure. Further studies will evaluate whether hs-TnT is associated with adverse outcomes in CRIC.
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